JP5415837B2 - Method for producing granules and tablets from a powdery functional substance having inferior compression moldability - Google Patents
Method for producing granules and tablets from a powdery functional substance having inferior compression moldability Download PDFInfo
- Publication number
- JP5415837B2 JP5415837B2 JP2009141165A JP2009141165A JP5415837B2 JP 5415837 B2 JP5415837 B2 JP 5415837B2 JP 2009141165 A JP2009141165 A JP 2009141165A JP 2009141165 A JP2009141165 A JP 2009141165A JP 5415837 B2 JP5415837 B2 JP 5415837B2
- Authority
- JP
- Japan
- Prior art keywords
- functional substance
- tablet
- particles
- binder
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000126 substance Substances 0.000 title claims description 72
- 239000008187 granular material Substances 0.000 title claims description 44
- 238000007906 compression Methods 0.000 title claims description 25
- 230000006835 compression Effects 0.000 title claims description 25
- 238000004519 manufacturing process Methods 0.000 title claims description 15
- 239000002245 particle Substances 0.000 claims description 59
- 239000011230 binding agent Substances 0.000 claims description 39
- 239000011362 coarse particle Substances 0.000 claims description 25
- 239000010419 fine particle Substances 0.000 claims description 22
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 20
- 229960002442 glucosamine Drugs 0.000 claims description 20
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 229920002678 cellulose Polymers 0.000 claims description 15
- 235000010980 cellulose Nutrition 0.000 claims description 15
- 239000001913 cellulose Substances 0.000 claims description 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- 239000000314 lubricant Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000004570 mortar (masonry) Substances 0.000 claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 3
- 239000003826 tablet Substances 0.000 description 65
- 239000000843 powder Substances 0.000 description 35
- 238000005469 granulation Methods 0.000 description 15
- 230000003179 granulation Effects 0.000 description 15
- 239000000463 material Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920002101 Chitin Polymers 0.000 description 5
- -1 hydroxypropyl Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 229920001661 Chitosan Polymers 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229940045110 chitosan Drugs 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 229940023476 agar Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011164 primary particle Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical class CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229960004583 pranlukast Drugs 0.000 description 2
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011163 secondary particle Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- LUTLAXLNPLZCOF-UHFFFAOYSA-N 1-Methylhistidine Natural products OC(=O)C(N)(C)CC1=NC=CN1 LUTLAXLNPLZCOF-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000583531 Alpinia purpurata Species 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- CCLQKVKJOGVQLU-QMMMGPOBSA-N L-homocarnosine Chemical compound NCCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 CCLQKVKJOGVQLU-QMMMGPOBSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- BRMWTNUJHUMWMS-LURJTMIESA-N N(tele)-methyl-L-histidine Chemical compound CN1C=NC(C[C@H](N)C(O)=O)=C1 BRMWTNUJHUMWMS-LURJTMIESA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000278713 Theora Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108700002498 homocarnosine Proteins 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
本発明は圧縮成形性に劣る粉末状の機能性物質から顆粒及び錠剤を製造する方法に関し、特に圧縮成形性に劣るグルコサミン粉末からその含有率及び錠剤硬度が流通に十分耐えうる錠剤を製造する方法に関する。 The present invention relates to a method for producing granules and tablets from a powdery functional substance having poor compression moldability, and in particular, a method for producing tablets whose content and tablet hardness can sufficiently withstand distribution from glucosamine powder having poor compression moldability. About.
医薬品や健康食品の有効成分である機能性物質を摂取する際の剤形としては、散剤、顆粒剤、カプセル剤、錠剤等がある。このうち錠剤は、取扱いや服用が容易であり、もっともよく使用されている。 Examples of dosage forms for ingesting functional substances that are active ingredients of pharmaceuticals and health foods include powders, granules, capsules and tablets. Of these, tablets are the most commonly used because they are easy to handle and take.
一般に、錠剤は、機能性物質と、結合剤、賦形剤、崩壊剤及び滑沢剤等の任意成分とを配合した混合粉末(場合により、水および/または有機溶媒を加えて造粒し、造粒した顆粒)をホッパーからこれを打錠機の回転盤の臼中に定量的に流し、上杵、下杵で圧縮することにより製造される。 In general, a tablet is a mixed powder containing a functional substance and optional components such as a binder, an excipient, a disintegrant and a lubricant (in some cases, granulated by adding water and / or an organic solvent, The granulated granules) are produced by quantitatively flowing them from a hopper into a mortar of a tablet machine and compressing them with an upper punch and a lower punch.
錠剤はこのように圧縮して成形される。そのため、機能性物質の粉末が本来的に圧縮成形性に劣る性質を有する場合は、その比率が高くなればなるほど、適当な硬度の錠剤に成形することが困難であり、その為、結合剤を増量して圧縮成形性を補う必要がある。ここで、圧縮成形性とは、粉末に圧力をかけた際に粉末の粒子同士が相互に結合する性質を示し、無定形の粉末を特定の形状に押し固めることが可能な特性をいう。 Tablets are compressed and molded in this way. Therefore, when the functional substance powder has inherently inferior compression moldability, the higher the ratio, the more difficult it is to form a tablet with an appropriate hardness. It is necessary to increase the amount to compensate for compression moldability. Here, the compression moldability indicates a property that particles of powder are bonded to each other when pressure is applied to the powder, and refers to a characteristic capable of pressing an amorphous powder into a specific shape.
しかし、錠剤中に含まれる結合剤が増量されると、対応して錠剤中の機能性物質の含有率が減少してしまう。逆に、機能性物質の含有率を高めるために結合剤の使用量を減らすと、錠剤の硬度が所望の水準以下に低下する。 However, when the amount of the binder contained in the tablet is increased, the content of the functional substance in the tablet is correspondingly reduced. Conversely, if the amount of the binder used is reduced in order to increase the content of the functional substance, the hardness of the tablet is lowered to a desired level or less.
特許文献1には、打錠加工に適さないグルコサミンの結晶粉体から、打錠加工に適した物性を有するグルコサミン顆粒を得ることができ、このグルコサミン顆粒を用いることにより、通常の圧縮成形によって、均質で適度に高い硬度を有するグルコサミン錠剤を得る技術が記載されている。
In
しかし、この技術においても、グルコサミンの結晶粉体を顆粒化し、錠剤に成形する際に比較的多量の結合剤を用いなければならず、製造されているグルコサミン錠剤のグルコサミン含有率は65質量%程度に過ぎない。 However, even in this technique, a relatively large amount of binder must be used when granulating glucosamine crystal powder and molding into tablets, and the glucosamine content of the manufactured glucosamine tablets is about 65% by mass. Only.
特許文献2には、プランルカスト水和物を流動化剤と混合して流動化した粉末に水溶性セルロースの水溶液を噴霧して造粒することにより、打錠に適した流動性を示す顆粒を製造する技術が記載されている。しかし、プランルカスト水和物の粉末は付着凝集性を有しており、圧縮成形性に劣るものではない。
それゆえ、この技術では結合剤を増量して圧縮成形性を補う必要がなく、少量の結合剤で錠剤の高い硬度を達成する必要性が記載されていない。また、錠剤は実際に製造されておらず、錠剤の硬度や有効成分の含有率が高められたことが示されていない。 Therefore, this technique does not require increasing the binder to supplement compression moldability and does not describe the need to achieve high tablet hardness with a small amount of binder. Moreover, the tablet is not actually manufactured, and it is not shown that the hardness of the tablet and the content of the active ingredient are increased.
本発明は上記従来の問題を解決するものであり、その目的とするところは、できるだけ少量の結合剤を用いて、圧縮成形性に劣る粉末状の機能性物質から高い硬度の錠剤を得ることにある。 The present invention solves the above-mentioned conventional problems, and its object is to obtain a tablet with high hardness from a powdery functional substance having inferior compression moldability by using as little binder as possible. is there.
本発明は、圧縮成形性に劣る粉末状の機能性物質に対し、微細化された造粒用結合剤を均一に付着させる工程;及び
造粒用結合剤を付着させた機能性物質の粒子同士を接触させることにより造粒を行う工程;
を包含し、両工程は同時に行われてもよい、顆粒の製造方法であって、
該造粒用結合剤が水溶性セルロース誘導体である顆粒の製造方法を提供する。
The present invention includes a step of uniformly adhering a refined granulating binder to a powdery functional substance having inferior compression moldability; and particles of the functional substance to which the granulating binder is adhered Granulating by bringing into contact;
A process for producing granules, wherein both steps may be performed simultaneously,
Provided is a method for producing granules, wherein the granulating binder is a water-soluble cellulose derivative.
ある一形態においては、前記水溶性セルロース誘導体はヒドロキシプロピルセルロース及びヒドロキシプロピルメチルセルロースからなる群から選択される少なくとも一種である。 In one certain form, the said water-soluble cellulose derivative is at least 1 type selected from the group which consists of a hydroxypropyl cellulose and a hydroxypropyl methylcellulose.
ある一形態においては、前記粉末状の機能性物質はグルコサミンである。 In one certain form, the said powdery functional substance is glucosamine.
ある一形態においては、前記粉末状の機能性物質は粗粒子、及び粗粒子の平均粒度に対して1/3以下の平均粒度を有する細粒子を混合したものである。 In one certain form, the said powdery functional substance is a mixture of coarse particles and fine particles having an average particle size of 1/3 or less of the average particle size of the coarse particles.
ある一形態においては、前記粗粒子と細粒子との混合比は、粗粒子100質量部に対して細粒子50〜500質量部である。 In one certain form, the mixing ratio of the said coarse particle and a fine particle is 50-500 mass parts of fine particles with respect to 100 mass parts of coarse particles.
ある一形態においては、前記機能性物質はグルコサミンであり、粗粒子の平均粒度は180μm以上である。 In one certain form, the said functional substance is glucosamine, and the average particle diameter of a coarse particle is 180 micrometers or more.
ある一形態においては、造粒用結合剤は、顆粒中の含有量が10質量%以下になるような量で用いられる。 In one certain form, the granulating binder is used in such an amount that the content in the granules is 10% by mass or less.
また、本発明は、上記いずれかの方法によって得られる顆粒を提供する。 The present invention also provides granules obtained by any of the above methods.
また、本発明は、上記顆粒を含む打錠末を筒状の臼に充填する工程;及び
臼に充填された顆粒を上杵・下杵で圧縮する工程;
を包含する錠剤の製造方法を提供する。
The present invention also includes a step of filling the tablet containing the granule into a cylindrical mortar; and a step of compressing the granule filled in the mortar with an upper punch and a lower punch;
The manufacturing method of the tablet including this is provided.
また、本発明は、上記方法によって得られる錠剤を提供する。 Moreover, this invention provides the tablet obtained by the said method.
ある一形態においては、前記錠剤における、結合剤、賦形剤、崩壊剤及び滑沢剤を合計した含有量が10質量%以下である。 In one certain form, content which combined the binder, the excipient | filler, the disintegrating agent, and the lubricant in the said tablet is 10 mass% or less.
本発明の錠剤は、圧縮成形性に劣る粉末状の機能性物質を含むにもかかわらず、その含有率が高く硬度も高い。つまり、錠剤中の機能性物質以外のいわゆる添加剤の配合率を少なくできるために、機能性物質の含有率を高くすることが出来る。その結果、利用者にとっては錠剤剤形が同一の場合は一日目安量が減る、もしくは一日目安量が同一の場合は錠剤剤形を小さくできる利益が得られる。 The tablet of the present invention has a high content and high hardness despite containing a powdery functional substance that is inferior in compression moldability. That is, since the blending ratio of so-called additives other than the functional substance in the tablet can be reduced, the content of the functional substance can be increased. As a result, it is possible for the user to obtain the benefit of reducing the daily dosage when the tablet dosage form is the same, or reducing the tablet dosage form when the daily dosage is the same.
顆粒の製造方法及び顆粒
機能性物質とは人体に摂取した後に、体内で意図される作用を奏する物質をいい、医薬品や健康食品でいう有効成分を含む概念である。本願発明の対象となる機能性物質は粉末状の機能性物質であり、特に圧縮成形性に劣る粉末状の機能性物質である。
The granule production method and the granule functional substance are substances that exhibit an intended action in the body after ingestion into the human body, and are concepts including active ingredients in pharmaceuticals and health foods. The functional substance that is the subject of the present invention is a powdery functional substance, in particular, a powdery functional substance that is inferior in compression moldability.
圧縮成形性に劣る粉末状の機能性物質とは、粉末の粒子そのものが相互に結合する性質が本来的に小さく、適当な硬度の錠剤に成形するためには、比較的高い割合で結合剤等を存在させなければならず、その結果、機能性物質自体の錠剤中の含有率を向上させることが困難であるものをいう。具体的には、例えば、従来の錠剤の製造方法では、単体で用いた場合でも錠剤中の含有率を、60%、70%又は75%を越えて増大させることができなかった粉末状機能性物質は圧縮成形性に劣るものに該当する。 The functional substance in the form of powder that is inferior in compression moldability is inherently small in the nature of the powder particles themselves to bind to each other. As a result, it is difficult to improve the content of the functional substance itself in the tablet. Specifically, for example, in the conventional tablet manufacturing method, even when used alone, the content in the tablet could not be increased beyond 60%, 70% or 75%, and the powdery functionality The substance falls under the category of inferior compression moldability.
例えば、グルコサミンは錠剤中の含有率は70%程度が限界とされている。 For example, the content of glucosamine in the tablet is limited to about 70%.
本発明の方法で錠剤化される機能性物質は、圧縮成形性に劣る粉末状の機能性物質以外の成分を含んでいてもよい。 The functional substance tableted by the method of the present invention may contain components other than the powdery functional substance having poor compression moldability.
かかる機能性物質(即ち、圧縮成形性に劣る粉末状の機能性物質以外の成分)としては、例えば、カルシウム、キトサン、キチン、ヒアルロン酸、セラミド、コンドロイチン硫酸、N−アセチルグルコサミン、コラーゲン、MSM、赤しょうがエキス、西洋ヤナギ、各種ポリフェノール(りんご由来、茶由来、グァバ由来、松由来、ブドウ由来等)、アミノ酸として、アルギニン、タウリン、グルタミン酸、ヒスチジン、分岐鎖アミノ酸(ロイシン、イソロイシン、バリン)などが使用される。また、ヒスチジン、1−メチルヒスチジン、3―メチルヒスチジン、アンセリン、カルノシン、ホモカルノシン、バレニンのようなイミダゾール化合物も併用することができる。その他、オクタコサノール、クエン酸、酢酸、キチンダイマー、キチンペンタマー、キトサンヘキサマー、オリゴグルコサミン、エイコサペンタエン酸、ドコサペンタエン酸、ドコサヘキサエン酸、トウガラシ、高麗人参、ビール酵母、パン酵母、酵母亜鉛、酵母セレンなどが挙げられる。 Examples of such a functional substance (that is, a component other than a powdery functional substance having poor compression moldability) include, for example, calcium, chitosan, chitin, hyaluronic acid, ceramide, chondroitin sulfate, N-acetylglucosamine, collagen, MSM, Red ginger extract, western willow, various polyphenols (from apple, tea, guava, pine, grape etc.), amino acids such as arginine, taurine, glutamic acid, histidine, branched chain amino acids (leucine, isoleucine, valine) used. Also, imidazole compounds such as histidine, 1-methylhistidine, 3-methylhistidine, anserine, carnosine, homocarnosine, and valenin can be used in combination. Others, octacosanol, citric acid, acetic acid, chitin dimer, chitin pentamer, chitosan hexamer, oligoglucosamine, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, red pepper, ginseng, beer yeast, baker's yeast, yeast zinc, yeast Examples include selenium.
しかし、圧縮成形性に劣る粉末状の機能性物質は、錠剤化の対象となる機能性成分の主成分を構成する。ここでいう主成分とは錠剤化の対象となる機能性成分の60質量%以上、好ましくは70質量%以上、より好ましくは80質量%以上を構成している成分をいう。 However, the powdery functional substance inferior in compression moldability constitutes the main component of the functional component to be tableted. The main component here means a component constituting 60% by mass or more, preferably 70% by mass or more, more preferably 80% by mass or more of the functional component to be tableted.
造粒用結合剤とは機能性物質の粒子を造粒する用途に用いられる結合剤をいう。造粒とは機能性物質の一次粒子を複数結合させて、凝集した二次粒子を形成することをいう。顆粒は二次粒子から構成され、その粒子寸法は一般に一次粒子の数十倍から数百倍である。 The granulating binder refers to a binder used for the purpose of granulating functional substance particles. Granulation refers to the formation of aggregated secondary particles by combining a plurality of primary particles of a functional substance. Granules are composed of secondary particles, and their particle size is generally tens to hundreds of times that of primary particles.
造粒用結合剤は人体に対する安全性に優れ、粉末の粒子同士を結合する能力が高いものが好ましい。また、微細化して粉末の粒子に均一に付着し易いものが好ましい。そのような造粒用結合剤の具体例は水溶性セルロース誘導体である。 The granulating binder is preferably one having excellent safety for human body and high ability to bind powder particles. Moreover, the thing which is refined | miniaturized and tends to adhere to the powder particle | grains uniformly is preferable. A specific example of such a granulating binder is a water-soluble cellulose derivative.
水溶性セルロース誘導体とは、セルロースの水酸基の水素原子の一部をメチル基、エチル基、プロピル基、ヒドロキシプロピル基またはヒドロキシエチル基等で置換することにより、水素結合を消失させた水溶性高分子である。例えば、ヒドロキシメチルセルロース、ヒドロキシメチルエチルセルロース、メチルセルロース、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース(HPC)、ヒドロキシプロピルメチルセルロース(HPMC)、ヒドロキシプロピルメチルセルロースフタレート(HPMCP)、ヒドロキシプロピルメチルセルロースアセテートスクシネート(HPMCAS)等が挙げられ、これらを一種以上適宜配合して用いることができる。好ましい水溶性セルロース誘導体は、ヒドロキシプロピルセルロースおよびヒドロキシプロピルメチルセルロースである。特に好ましい水溶性セルロース誘導体はヒドロキシプロピルメチルセルロースである。 A water-soluble cellulose derivative is a water-soluble polymer in which hydrogen bonds are lost by substituting part of the hydrogen atoms of the hydroxyl group of cellulose with methyl, ethyl, propyl, hydroxypropyl or hydroxyethyl groups. It is. Examples include hydroxymethylcellulose, hydroxymethylethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxypropylmethylcellulose phthalate (HPMCP), and hydroxypropylmethylcellulose acetate succinate (HPMCAS). One or more of these can be appropriately blended and used. Preferred water-soluble cellulose derivatives are hydroxypropylcellulose and hydroxypropylmethylcellulose. A particularly preferred water-soluble cellulose derivative is hydroxypropylmethylcellulose.
造粒用結合剤は、例えば水又は水性媒体に溶解することにより水性液にして、この水溶液を噴霧することにより微細化する。また、噴霧した造粒用結合剤の水性液を機能性物質の粉末に散布することにより、その粉末の粒子に対して均一に付着させる。その際に、一般には、機能性物質の粉末は流動させて造粒用結合剤の水性液が均一に粒子と接触させられる。機能性物質の粉末は攪拌することにより流動させてよく、また同時に加熱して乾燥させてもよい。機能性物質の粉末に熱風を吹き込んで流動と乾燥を同時に行ってもよい。 The granulating binder is made into an aqueous liquid by, for example, dissolving in water or an aqueous medium, and finely sprayed by spraying this aqueous solution. Moreover, the sprayed aqueous liquid of the granulating binder is sprayed on the powder of the functional substance, so that it adheres uniformly to the particles of the powder. At that time, generally, the powder of the functional substance is flowed so that the aqueous liquid of the granulating binder is uniformly brought into contact with the particles. The powder of the functional substance may be fluidized by stirring, or may be simultaneously heated and dried. Fluidization and drying may be performed simultaneously by blowing hot air into the functional substance powder.
使用する造粒用結合剤の量は得られる顆粒に対して10質量%以下、好ましくは2〜8質量%、より好ましくは3〜6質量%、更に好ましくは3〜5質量%となるように調節される。造粒用結合剤の量がこれより多くなると錠剤中の機能性物質の含有率を十分に向上させることが困難になる。また、造粒時間が長くなり、製造には不向きである。 The amount of the granulating binder used is 10% by mass or less, preferably 2 to 8% by mass, more preferably 3 to 6% by mass, and further preferably 3 to 5% by mass with respect to the granules to be obtained. Adjusted. When the amount of the granulating binder is larger than this, it becomes difficult to sufficiently improve the content of the functional substance in the tablet. Moreover, granulation time becomes long and is unsuitable for manufacture.
次いで、造粒用結合剤を付着させた機能性物質の粒子同士を接触させることにより、これらを相互に付着させて造粒させる。例えば、造粒用結合剤の水溶液を散布しながら機能性物質の粉末を流動させると、造粒用結合剤が付着した機能性物質の粒子同士が接触して、造粒が生じる。この場合、機能性物質の粒子に対し、微細化された造粒用結合剤を均一に付着させることと、造粒用結合剤を付着させた機能性物質の粒子同士を接触させることが同時に行われることになる。 Subsequently, the particles of the functional material to which the binder for granulation is adhered are brought into contact with each other to be adhered to each other and granulated. For example, when a powder of a functional substance is flowed while spraying an aqueous solution of a granulating binder, particles of the functional substance to which the granulating binder is attached come into contact with each other to cause granulation. In this case, the finely divided granulating binder is uniformly attached to the functional substance particles, and the functional substance particles to which the granulating binder is adhered are simultaneously brought into contact with each other. It will be.
粉末状の機能性物質は平均粒度が60〜200μm、好ましくは65〜185μm、より好ましくは70〜170μmである。機能性物質の平均粒度が60μm未満であると凝集性が強くなり粉末が大きな固まりになり易く、粉末が流動せず粒子同士の接触を妨げることになる。機能性物質の平均粒度が200μmを超えると、錠剤に成形する際に粒子間の隙間が大きくなり、錠剤中の機能性物質の含有率を十分に向上させることが困難になる。また、粒子同士の接触面積が小さくなるため、圧縮成形性に劣る顆粒となってしまう。 The powdery functional substance has an average particle size of 60 to 200 μm, preferably 65 to 185 μm, more preferably 70 to 170 μm. If the average particle size of the functional substance is less than 60 μm, the cohesiveness becomes strong and the powder tends to be agglomerated, and the powder does not flow and prevents the particles from contacting each other. When the average particle size of the functional substance exceeds 200 μm, the gap between the particles becomes large when forming into a tablet, and it becomes difficult to sufficiently improve the content of the functional substance in the tablet. Moreover, since the contact area of particle | grains becomes small, it will become a granule inferior to compression moldability.
粉末状の機能性物質は、成形された錠剤中にできるだけ密に充填されることが好ましい。錠剤中の機能性物質の含有率を向上させるのに有効だからである。そのためには、例えば、比較的寸法が大きい粗粒子間の隙間に、比較的寸法が小さい細粒子が細密充填されているような充填形態が好ましい。かかる場合、細粒子の粒子径は、理論的には粗粒子の粒子径に対して1/6〜1/3である。 The powdered functional substance is preferably packed as densely as possible in the molded tablet. This is because it is effective in improving the content of the functional substance in the tablet. For this purpose, for example, a filling form in which fine particles having relatively small dimensions are closely packed in gaps between coarse particles having relatively large dimensions is preferable. In such a case, the particle diameter of the fine particles is theoretically 1/6 to 1/3 with respect to the particle diameter of the coarse particles.
細密充填の充填形態を実現するために、粉末状の機能性物質は、粒子寸法が一般的なものよりも大きい粗粒子と、粒子寸法が上記粗粒子間の隙間に細密充填される程度の細粒子とを、混合して用いることが好ましい。細粒子の平均粒度は、好ましくは粗粒子の平均粒度に対して1/3以下、例えば1/6〜1/3、又は1/5〜1/4である。但し、細粒子の平均粒度の下限は特に制限されない。 In order to realize a finely packed form, the functional substance in powder form has coarse particles having a particle size larger than that of a general one and fine particles so that the particle size is closely packed in the gaps between the coarse particles. It is preferable to mix and use the particles. The average particle size of the fine particles is preferably 1/3 or less, for example, 1/6 to 1/3, or 1/5 to 1/4 with respect to the average particle size of the coarse particles. However, the lower limit of the average particle size of the fine particles is not particularly limited.
細粒子の平均粒度が粗粒子の平均粒度に対して1/3よりも大きいと細粒子は粗粒子の間の隙間に細密充填されず、錠剤中の機能性物質の含有率を十分に向上させることが困難になる。 Greater when fine particles than 1/3 the average particle size to the average particle size of the coarse particles of the fine particles is not close-packed in the gap between the coarse particles to sufficiently improve the content of the functional substance in the tablet It becomes difficult.
尚、細粒子の粒子寸法の精度は厳密である必要はない。例えば、細粒子の平均粒度が粗粒子の平均粒度に対して1/3以上であっても、顆粒を調製し、錠剤に成形する過程で粒子同士が摩擦、圧迫などして粒子寸法が変化し、結果として、細粒子が粗粒子間の隙間に細密充填される程度の大きさであれば許容される。 Note that the accuracy of the particle size of the fine particles need not be strict. For example, even if the average particle size of the fine particles is 1/3 or more than the average particle size of the coarse particles, the particle size changes due to friction and compression between the particles in the process of preparing granules and forming into tablets. As a result, it is acceptable if the size is such that the fine particles are closely packed in the gaps between the coarse particles.
粗粒子の平均粒度は、例えば180〜300μm、好ましくは200〜260μm、より好ましくは210〜240μmとする。粗粒子の平均粒度300μmを超えると細粒子とのバランスが崩れ、圧縮成形性に劣る顆粒となってしまう。また、細粒子の平均粒度は、例えば20〜100μm、好ましくは30〜90μm、より好ましくは40〜80μmとする。 The average particle size of the coarse particles is, for example, 180 to 300 μm, preferably 200 to 260 μm, more preferably 210 to 240 μm. When the average particle size of the coarse particles exceeds 300 μm, the balance with the fine particles is lost, and the granules are inferior in compression moldability. The average particle size of the fine particles is, for example, 20 to 100 μm, preferably 30 to 90 μm, and more preferably 40 to 80 μm.
ここで、平均粒度とは、その一次粒子の体積平均粒子径(MV)を意味し、例えば一般に用いられているレーザー回折式の粒度分布測定装置(例えば、日機装株式会社製「マイクロトラック粒度分析計MT3300EX」)により求めることができる。 Here, the average particle size means the volume average particle size (MV) of the primary particles. For example, a commonly used laser diffraction type particle size distribution measuring device (for example, “Microtrac particle size analyzer manufactured by Nikkiso Co., Ltd.”). MT3300EX ").
機能性物質の粒子寸法をメッシュで表現すると、粗粒子は、例えば16〜50メッシュ、好ましくは20〜45メッシュ、より好ましくは30メッシュ〜40メッシュを通過した大きさである。また、細粒子は、例えば50〜180メッシュ、好ましくは60〜150メッシュ、より好ましくは80メッシュ〜100メッシュである。ここで、メッシュとは、ふるい網(JIS Z8801)の目の寸法及びこれを通過する粒子の寸法を表す単位である。数値の意味は、ふるい網1インチ当たりの網目の数である。 When the particle size of the functional substance is expressed as a mesh, the coarse particles have a size that has passed, for example, 16 to 50 mesh, preferably 20 to 45 mesh, more preferably 30 to 40 mesh. The fine particles are, for example, 50 to 180 mesh, preferably 60 to 150 mesh, more preferably 80 mesh to 100 mesh. Here, the mesh is a unit representing the size of the mesh of the sieve net (JIS Z8801) and the size of particles passing through it. The meaning of the numerical value is the number of meshes per inch of sieve mesh.
粗粒子と細粒子との混合比は、両方の粒子径を考慮して、粗粒子間の隙間に細粒子が細密充填されるように適宜調整される。一般には、粗粒子100質量部に対して細粒子50〜500質量部、好ましくは100〜400質量部、より好ましくは200〜300質量部である。 The mixing ratio of the coarse particles and the fine particles is appropriately adjusted so that the fine particles are densely packed in the gaps between the coarse particles in consideration of both particle sizes. Generally, it is 50-500 mass parts of fine particles with respect to 100 mass parts of coarse particles, Preferably it is 100-400 mass parts, More preferably, it is 200-300 mass parts.
また、粉末状の機能性物質はかさ密度が0.45〜0.61g/ml、好ましくは0.46〜0.60g/ml、より好ましくは0.47〜0.59g/mlである。機能性物質のかさ密度が0.45g/ml未満であると凝集性が強くなり粉末が大きな固まりになり易く、粉末が流動せず粒子同士の接触を妨げることになる。機能性物質のかさ密度が0.61g/mlを超えると、錠剤に成形する際に粒子間の隙間が大きくなり、錠剤中の機能性物質の含有率を十分に向上させることが困難になる。また、粒子同士の接触面積が小さくなるため、圧縮成形性に劣る顆粒となってしまう。 The powdery functional substance has a bulk density of 0.45 to 0.61 g / ml, preferably 0.46 to 0.60 g / ml, more preferably 0.47 to 0.59 g / ml. If the bulk density of the functional substance is less than 0.45 g / ml, the cohesiveness becomes strong and the powder tends to be agglomerated, and the powder does not flow and prevents the particles from contacting each other. When the bulk density of the functional substance exceeds 0.61 g / ml, a gap between particles becomes large when forming into a tablet, and it becomes difficult to sufficiently improve the content of the functional substance in the tablet. Moreover, since the contact area of particle | grains becomes small, it will become a granule inferior to compression moldability.
ここで、かさ密度とは単位かさ体積あたりの粉体質量を意味し、体積が既知の容器に粉体を充填して、その質量を測定することにより決定される。かさ密度の測定は、例えば、日本薬局方に説明されている操作に従って行えばよい。 Here, the bulk density means the powder mass per unit bulk volume, and is determined by filling the powder in a container with a known volume and measuring the mass. The bulk density may be measured, for example, according to an operation described in the Japanese Pharmacopoeia.
粉末状の機能性物質を造粒するのに使用される造粒機には特に制限はなく、例えば、流動層造粒機、撹拌造粒機、押出し造粒機等が使用できる。 There is no particular limitation on the granulator used for granulating the powdered functional substance, and for example, a fluidized bed granulator, a stirring granulator, an extrusion granulator, or the like can be used.
本発明の方法では、顆粒の物性、機能性物質の含有率に大きな影響を与えない範囲で造粒用副基材を配合してもよく、その場合、粉末状の機能性物質と造粒用副基材とを、造粒前に予め混合した後造粒加工してもよいし、造粒後に添加してもよい。その際、澱粉、デキストリンなどの澱粉分解物、カラギーナン、寒天、アルギン酸、グアーガム、キトサン、キサンタンガムなどの多糖類、砂糖、ぶどう糖、乳糖、麦芽糖などの単糖、二糖類、フラクトオリゴ糖、マルトオリゴ糖、イソマルトオリゴ糖、ガラクトオリゴ糖、キチンオリゴ糖、キトサンオリゴ糖などのオリゴ糖、マルチトール、ソルビトール、キシリトール、エリスリトールなどの糖アルコール、結晶セルロース等を、造粒用副基材として用いることができる。また、前記糖類以外でも、顆粒状製剤の調整に通常の用いられる、増粘剤、乳化剤等の成分を造粒用副基材として用いることができる。 In the method of the present invention, a granulating sub-base material may be blended within a range that does not significantly affect the physical properties of the granules and the content of the functional material. The auxiliary base material may be pre-mixed before granulation and then granulated, or may be added after granulation. At that time, starch, dextrin and other starch degradation products, carrageenan, agar, alginic acid, guar gum, chitosan, xanthan gum and other polysaccharides, sugar, glucose, lactose, maltose and other monosaccharides, disaccharides, fructooligosaccharides, malto-oligosaccharides, iso Oligosaccharides such as maltooligosaccharide, galactooligosaccharide, chitin oligosaccharide and chitosan oligosaccharide, sugar alcohols such as maltitol, sorbitol, xylitol and erythritol, crystalline cellulose and the like can be used as the auxiliary base material for granulation. In addition to the sugars, components such as thickeners and emulsifiers that are commonly used for preparing granular preparations can be used as the auxiliary base material for granulation.
これらの造粒用副基材を適宜配合して造粒加工することで、造粒加工及び/又は打錠加工時の生産性を高めることができ、また、顆粒製品の形状安定性を更に改善することができる。造粒用副基材の使用量は特に規定されないが、機能性物質の含有率を低下させない程度に調節すればよい。一般には顆粒中の含有量が20質量%以下、好ましくは10質量%以下になるように、調節される By mixing these sub-base materials for granulation as appropriate and granulating, the productivity during granulation and / or tableting can be increased, and the shape stability of granule products is further improved. can do. The amount of the granulation sub-base material is not particularly defined, but may be adjusted to such an extent that the content of the functional substance is not lowered. Generally, the content in the granule is adjusted to 20% by mass or less, preferably 10% by mass or less.
このようにして得られた顆粒は、必要に応じて乾燥し、含有する水や有機溶媒を除去する。乾燥温度は、20〜90℃、好ましくは30〜85℃、より好ましくは65〜80℃である。 The granules thus obtained are dried as necessary to remove the contained water and organic solvent. The drying temperature is 20 to 90 ° C, preferably 30 to 85 ° C, more preferably 65 to 80 ° C.
得られた顆粒は、機能性物質以外の成分の含量が3〜10質量%であり、且つ、嵩比重が25〜40g/mlで、より好ましくは28〜35g/mlである。また、水分含量は3.0質量%以下であることが好ましく、2.0質量%以下であることがより好ましい。更に、顆粒は、16〜22メッシュに適宜整粒してもよい。 The obtained granule has a content of components other than the functional substance of 3 to 10% by mass and a bulk specific gravity of 25 to 40 g / ml, more preferably 28 to 35 g / ml. Further, the water content is preferably 3.0% by mass or less, and more preferably 2.0% by mass or less. Furthermore, the granules may be appropriately sized to 16-22 mesh.
錠剤の製造方法及び錠剤
乾燥した顆粒は、要すれば、整粒を行い、錠剤を製造するために必要な基材(例えば、結合剤、賦形剤、崩壊剤および滑沢剤等)を加えて打錠末を得、これを圧縮成形して錠剤とする。必要な基材としては、一般に顆粒や錠剤を作るために使用するものを使うことができる。具体的には、澱粉、デキストリンなどの澱粉分解物、カラギーナン、寒天、アルギン酸、グアーガム、キトサン、キサンタンガムなどの多糖類、砂糖、ぶどう糖、乳糖、麦芽糖などの単糖、二糖類、フラクトオリゴ糖、マルトオリゴ糖、イソマルトオリゴ糖、ガラクトオリゴ糖、キチンオリゴ糖、キトサンオリゴ糖などのオリゴ糖、マルチトール、ソルビトール、キシリトール、エリスリトールなどの糖アルコール、結晶セルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース等のセルロース類、ポリビニルピロリドン等の合成高分子、アラビアゴム、寒天、プルラン、微粒酸化ケイ素、α化デンプン、部分α化デンプン、CMC-Ca、デンプングリコール酸ナトリウム、ステアリン酸マグネシウム、ステアリン酸カルシウム、ステアリン酸、ショ糖脂肪酸エステル、硬化油、植物油脂等が挙げられる。
The tablet manufacturing method and tablet- dried granules are sized, if necessary, and added with the necessary base materials (for example, binders, excipients, disintegrants, lubricants, etc.) to manufacture tablets. To obtain a tableting powder, which is compression-molded into tablets. As a necessary base material, what is generally used in order to make a granule or a tablet can be used. Specifically, starch degradation products such as starch and dextrin, polysaccharides such as carrageenan, agar, alginic acid, guar gum, chitosan and xanthan gum, monosaccharides such as sugar, glucose, lactose and maltose, disaccharides, fructooligosaccharides, maltooligosaccharides , Oligosaccharides such as isomaltoligosaccharide, galactooligosaccharide, chitin oligosaccharide, chitosan oligosaccharide, sugar alcohols such as maltitol, sorbitol, xylitol, erythritol, celluloses such as crystalline cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone Synthetic polymers such as gum arabic, agar, pullulan, fine silicon oxide, pregelatinized starch, partially pregelatinized starch, CMC-Ca, sodium starch glycolate, magnesium stearate, stearin Calcium, stearate, sucrose fatty acid esters, hydrogenated oils, vegetable oils and the like.
これらの基材は、一つまたは二つ以上組み合わせて使用されるが、その機能に応じて打錠用結合剤、賦形剤、崩壊剤、滑沢剤に分けて使うことが望ましい。このように製造した錠剤には、フィルムコーティングまたは糖衣コーティングを施すコーティング工程を適宜設けてもよい。 These substrates are used singly or in combination of two or more, but it is desirable to use them divided into tableting binders, excipients, disintegrants and lubricants according to their functions. The tablets produced as described above may be appropriately provided with a coating process for applying film coating or sugar coating.
錠剤の製造は、例えば、打錠末を筒状の臼に充填し、臼に充填された顆粒をすりきり板
で一定量にすりきり、上下の杵で圧縮して行われる。打錠機は公知のものがなんらの制限もなく使用することができる。打錠圧は錠剤硬度が流通に十分耐えうる硬度になるように調整すればよい。
Tablets are produced, for example, by filling tablet powder into a cylindrical mortar, grinding the granule filled in the mortar to a fixed amount with a grinding plate, and compressing it with upper and lower scissors. A known tableting machine can be used without any limitation. The tableting pressure may be adjusted so that the tablet hardness is sufficient to withstand circulation.
このようにして得られた錠剤は、機能性物質以外の成分(例えば、結合剤、賦形剤、崩壊剤及び滑沢剤等)を合計した含有率が15質量%以下、より好ましくは例えば5〜10質量%であり、その場合の錠剤硬度が3〜10kgfである。尚、本明細書において、単に「結合剤」と言うときは、造粒用結合剤及び打錠用結合剤の両方を含むものとする。 The tablet thus obtained has a total content of components other than the functional substance (for example, binder, excipient, disintegrant, lubricant, etc.) of 15% by mass or less, more preferably, for example, 5 -10 mass%, and the tablet hardness in that case is 3-10 kgf. In the present specification, the term “binder” includes both a granulating binder and a tableting binder.
また、上記打錠末には錠剤の硬度を損なわない範囲で圧縮成形性に劣る粉末状の機能性物質以外の機能性物質を配合してもよい。圧縮成形性に劣る粉末状の機能性物質以外の機能性物質には、本発明の顆粒の製造方法を説明した際に例示したものが含まれる。かかる機能性物質の好ましい使用量は、上述の通り、圧縮成形性に劣る粉末状の機能性物質が錠剤に含まれる機能性物質の主成分になる範囲である。 Moreover, you may mix | blend functional substances other than the powdery functional substance which is inferior to compression moldability in the said tableting powder in the range which does not impair the hardness of a tablet. Examples of the functional substance other than the powdery functional substance inferior in compression moldability include those exemplified when the production method of the granule of the present invention is described. As described above, a preferable amount of such a functional substance used is a range in which a powdery functional substance having inferior compression moldability is the main component of the functional substance contained in the tablet.
以下の実施例により本発明を更に具体的に説明するが、本発明はこれらに限定されない。特に断らない限り、用いる材料の比率及び量は質量基準である。 The following examples further illustrate the present invention, but the present invention is not limited thereto. Unless otherwise noted, the ratios and amounts of materials used are on a mass basis.
実施例1
顆粒の調製
粒子寸法が83メッシュ篩過のグルコサミン粉末(甲陽ケミカル(株)社製「コーヨーグルコサミン80」)及び粒子寸法が42メッシュ篩過のグルコサミン粉末(甲陽ケミカル(株)社製「コーヨーグルコサミン」)を質量比3/1で混合して、造粒用機能性物質とした。造粒用結合剤としてヒドロキシプロピルメチルセルロース(信越化学工業株式会社製「メトローズSE−06」)を準備し、その8%水溶液を調製して噴霧液を得た。
Example 1
Preparation of granules Glucosamine powder with a particle size of 83 mesh sieve (“Koyo Glucosamine 80” manufactured by Koyo Chemical Co., Ltd.) and Glucosamine powder with a particle size of 42 mesh sieve (“Koyo Glucosamine” manufactured by Koyo Chemical Co., Ltd.) ) At a mass ratio of 3/1 to obtain a functional substance for granulation. Hydroxypropyl methylcellulose (“Metroze SE-06” manufactured by Shin-Etsu Chemical Co., Ltd.) was prepared as a binder for granulation, and an 8% aqueous solution thereof was prepared to obtain a spray solution.
流動造粒装置(株式会社パウレック社製「流動層造粒機MP−01」)を用いて、造粒用機能性物質に噴霧液を均一に散布しながら、常法に従い造粒加工した。その際、給気温度は75℃とし、噴霧液の噴霧速度は6〜10ml/minとした。また、各成分の量は、形成される錠剤を100%として、機能性物質が94.48%、造粒用結合剤が4.17%となるように調節した。 Using a fluidized granulator ("Fluidized bed granulator MP-01" manufactured by POWREC Co., Ltd.), granulation was performed according to a conventional method while spraying the spray liquid uniformly on the functional material for granulation. At that time, the supply air temperature was 75 ° C., and the spray rate of the spray liquid was 6 to 10 ml / min. In addition, the amount of each component was adjusted so that the formed tablet was 100%, the functional substance was 94.48%, and the granulating binder was 4.17%.
得られた造粒物を水分が2%以下になるまで温度80℃にて乾燥し、乾燥後、16もしくは20メッシュ篩を用いて整粒を行いグルコサミン含有顆粒を得た。 The obtained granulated product was dried at a temperature of 80 ° C. until the water content became 2% or less, and after drying, the particles were sized using a 16 or 20 mesh sieve to obtain glucosamine-containing granules.
顆粒のかさ密度の測定
得られた顆粒のかさ密度の測定を行った。かさ密度は、顆粒を100mlの容器にすり切り一杯充填して、重量を測定後、次式によって算出した。
Measurement of bulk density of granule The bulk density of the obtained granule was measured. The bulk density was calculated by the following formula after the granule was ground and filled into a 100 ml container, and the weight was measured.
嵩比重[g/ml]=グルコサミン顆粒重量[g]/100ml
結果を表1に示す。
Bulk specific gravity [g / ml] = Glucosamine granule weight [g] / 100 ml
The results are shown in Table 1.
錠剤の調製
得られたグルコサミン含有顆粒に、結晶セルロース(旭化成ケミカルズ株式会社製「セオラスUF−F702」)及び滑沢剤としてステアリン酸カルシウム(堺化学社製)を混合して打錠末を得た。打錠機(畑鉄工所製「HT−AP12SS−U」)を用いて打錠末を打錠加工し、8mm丸φ250mgの錠剤を得た。その際、打錠圧は5〜15kNの範囲で変化させた。また、各成分の量は、形成される錠剤を100%として、結晶セルロースが0.55%、ステアリン酸カルシウムが0.80%となるように調節した。
Preparation of Tablets The obtained glucosamine-containing granules were mixed with crystalline cellulose (“Theoras UF-F702” manufactured by Asahi Kasei Chemicals Corporation) and calcium stearate (manufactured by Sakai Chemical Co., Ltd.) as a lubricant to obtain a tableting powder. The tableting powder was tableted using a tableting machine ("HT-AP12SS-U" manufactured by Hata Iron Works) to obtain 8 mm round tablets with a diameter of 250 mg. At that time, the tableting pressure was changed in the range of 5 to 15 kN. The amount of each component was adjusted such that the formed tablet was 100%, the crystalline cellulose was 0.55%, and the calcium stearate was 0.80%.
錠剤の硬度の測定
富山産業株式会社製「錠剤破壊強度測定器TH−303MP」を用いて得られた錠剤の硬度を測定した。結果を図1に示す。
Measurement of Tablet Hardness The hardness of the tablets obtained was measured using “Tablet Breaking Strength Meter TH-303MP” manufactured by Toyama Sangyo Co., Ltd. The results are shown in FIG.
実施例2〜6、参考例1〜3
機能性物質(グルコサミン)の粒子構成を表1の「粒子の混合比」の欄に示したように変更すること以外は実施例1と同様にして錠剤を調製し、硬度を測定した。結果を図1に示す。
Examples 2-6, Reference Examples 1-3
A tablet was prepared and the hardness was measured in the same manner as in Example 1 except that the particle structure of the functional substance (glucosamine) was changed as shown in the column of “particle mixing ratio” in Table 1. The results are shown in FIG.
比較例1
ヒドロキシプロピルメチルセルロースの代わりに水を噴霧して行い、造粒部にヒドロキシプロピルメチルセルロースを4.72%添加して造粒すること以外は実施例1と同様にして錠剤を調製し、硬度を測定した。結果を図1に示す。
Comparative Example 1
A tablet was prepared in the same manner as in Example 1 except that it was sprayed with water instead of hydroxypropylmethylcellulose, and 4.72% of hydroxypropylmethylcellulose was added to the granulated part and granulated, and the hardness was measured. . The results are shown in FIG.
比較例2
ヒドロキシプロピルメチルセルロースの代わりにデキストリン(松谷化学工業株式会社製「パインデックス#100」)を用いること以外は実施例1と同様にして錠剤を調製し、硬度を測定した。結果を図1に示す。
Comparative Example 2
Tablets were prepared in the same manner as in Example 1 except that dextrin (“Paindex # 100” manufactured by Matsutani Chemical Industry Co., Ltd.) was used instead of hydroxypropylmethylcellulose, and the hardness was measured. The results are shown in FIG.
表1に示されている通り、比較例の錠剤は流通に耐えうる硬度が得られなかった。実施例1、3の錠剤は十分な硬度が得られた。その他の実施例は実施例1、3ほど高くないが流通に耐えうる硬度が得られた。実施例9は、粉末凝集性が強く、流動層造粒機内で流動しない等の製造上の問題があったが、最も高い錠剤硬度を示した。 As shown in Table 1, the tablet of the comparative example could not obtain a hardness that could withstand distribution. The tablets of Examples 1 and 3 had sufficient hardness. Other examples were not as high as those in Examples 1 and 3, but the hardness to withstand circulation was obtained. Example 9 had strong powder cohesiveness and had production problems such as not flowing in a fluidized bed granulator, but showed the highest tablet hardness.
Claims (9)
造粒用結合剤を付着させた機能性物質の粒子同士を接触させることにより造粒を行う工程;
を包含し、両工程は同時に行われてもよい、顆粒の製造方法であって、
該粉末状の機能性物質が粗粒子、及び粗粒子の平均粒度に対して1/3以下の平均粒度を有する細粒子を混合したグルコサミンであり、
該造粒用結合剤が水溶性セルロース誘導体である顆粒の製造方法。 A step of uniformly adhering a refined granulating binder to a powdered functional substance having inferior compression moldability; and contacting particles of the functional substance to which the granulating binder is adhered The step of granulating by
A process for producing granules, wherein both steps may be performed simultaneously,
The powdery functional substance is glucosamine in which coarse particles and fine particles having an average particle size of 1/3 or less of the average particle size of the coarse particles are mixed,
A method for producing granules, wherein the granulating binder is a water-soluble cellulose derivative.
臼に充填された顆粒を上杵・下杵で圧縮する工程;
を包含する錠剤の製造方法。 Filling the tablet with the tablet containing the granule according to claim 6 into a cylindrical mortar; and compressing the granule filled in the mortar with upper and lower punches;
A method for producing a tablet comprising
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009141165A JP5415837B2 (en) | 2009-06-12 | 2009-06-12 | Method for producing granules and tablets from a powdery functional substance having inferior compression moldability |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009141165A JP5415837B2 (en) | 2009-06-12 | 2009-06-12 | Method for producing granules and tablets from a powdery functional substance having inferior compression moldability |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010285381A JP2010285381A (en) | 2010-12-24 |
JP5415837B2 true JP5415837B2 (en) | 2014-02-12 |
Family
ID=43541366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009141165A Active JP5415837B2 (en) | 2009-06-12 | 2009-06-12 | Method for producing granules and tablets from a powdery functional substance having inferior compression moldability |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5415837B2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5826473B2 (en) * | 2010-09-16 | 2015-12-02 | 協和発酵バイオ株式会社 | High unit glucosamine granule for direct hitting |
JP5740633B2 (en) * | 2011-06-03 | 2015-06-24 | 株式会社東洋新薬 | Tablet manufacturing method and tablet |
JP6032917B2 (en) * | 2012-03-29 | 2016-11-30 | 小林製薬株式会社 | tablet |
JP6588666B2 (en) * | 2014-03-28 | 2019-10-09 | 国立大学法人 東京大学 | Agent containing imidazole dipeptide |
CN107206094A (en) * | 2015-01-30 | 2017-09-26 | 协和发酵生化株式会社 | Contain the tablet and its manufacture method of functional materials with high content |
CN108883130B (en) * | 2016-04-01 | 2021-06-22 | 株式会社吴羽 | Tablet containing spherical adsorbent carbon for oral administration and method for producing same |
JP6430679B2 (en) * | 2016-04-01 | 2018-11-28 | 株式会社クレハ | Tablet containing spherical adsorption charcoal for oral administration |
JP6839546B2 (en) * | 2017-01-23 | 2021-03-10 | 株式会社ファンケル | Carrot powder-containing tablets |
JP6940356B2 (en) * | 2017-09-29 | 2021-09-29 | 株式会社ファンケル | N-Acetylglucosamine tablets |
KR102633916B1 (en) | 2018-10-31 | 2024-02-06 | (주)아모레퍼시픽 | Granular Composition Comprising Dietary Fiber from Green Tea and Method for Preparing the Same |
KR102673223B1 (en) | 2018-10-31 | 2024-06-07 | (주)아모레퍼시픽 | Granular Composition Comprising Dietary Fiber from Green Tea and Method for Preparing the Same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4674955B2 (en) * | 2000-11-10 | 2011-04-20 | ロート製薬株式会社 | Amino sugar-containing preparation |
US7198653B2 (en) * | 2003-07-31 | 2007-04-03 | Delavau Llc | Calcium carbonate granulation |
JP2006036644A (en) * | 2004-07-22 | 2006-02-09 | Yaizu Suisankagaku Industry Co Ltd | Manufacturing method of glucosamine granule, glucosamine granule and glucosamine tablet |
JP2007137802A (en) * | 2005-11-16 | 2007-06-07 | Takeda Chem Ind Ltd | Method for producing tablet |
JP2007238486A (en) * | 2006-03-07 | 2007-09-20 | Yaizu Suisankagaku Industry Co Ltd | Method for producing tablet containing glucosamine, glucosamine-containing tablet and glucosamine-containing granule |
-
2009
- 2009-06-12 JP JP2009141165A patent/JP5415837B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2010285381A (en) | 2010-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5415837B2 (en) | Method for producing granules and tablets from a powdery functional substance having inferior compression moldability | |
G Mirani et al. | Direct compression high functionality excipient using coprocessing technique: A brief review | |
EP2287234A1 (en) | Cellulose powder having excellent segregation preventive effect, and compositions thereof | |
JPS62149632A (en) | Solid medicine | |
CN102413819A (en) | Compressible and free-flow co-agglomerates of mannitol and granular starch | |
TWI695722B (en) | Solid preparation outer layer composition and easy-to-take solid preparation containing the outer layer composition | |
CN104582731A (en) | Solid pharmaceutical preparation containing levothyroxine | |
Nadaf et al. | Evaluation of Prosopis africana seed gum as an extended release polymer for tablet formulation | |
JP6416479B2 (en) | Solid paste preparation | |
JP2017122056A (en) | Production methods of pharmaceutical-containing granulated materials | |
JP2017521473A (en) | Powdered directly compressible grade polyvinyl alcohol | |
JP5919290B2 (en) | Compressible and highly viscous polysaccharide and polyol powders | |
JP5879668B2 (en) | Method for producing starch granules and orally disintegrating tablet | |
TWI829920B (en) | Pharmaceutical preparation and method for preparation thereof | |
CN102048736A (en) | Dasatinib pharmaceutical composition and preparation method thereof | |
CN102349915A (en) | Acetaminophen, caffeine, chlorphenamine maleate, and vitamin C preparation and preparation method thereof | |
US8821942B1 (en) | Highly compressible, low density ground calcium carbonate granulation and a related method of preparation | |
Apeji et al. | Comparative analysis of co-processed starches prepared by three different methods | |
Bakre et al. | Material, compressional and tableting properties of ipomea batatas (sweet potato) starch co-processed with silicon dioxide | |
JP4170062B2 (en) | Solid agent | |
JPWO2018159673A1 (en) | Erythritol granules and production method thereof, and tablet production method and tablet using the same | |
CN109700773B (en) | Ticagrelor preparation composition and preparation method thereof | |
JP5680607B2 (en) | Stable solid preparation and production method thereof | |
JP2018083923A (en) | Cellulose dispersion, method for producing cellulose dispersion, molded body composition, molded body, and method for producing molded body composition | |
JPWO2020218517A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120405 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130816 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131017 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131114 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5415837 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |